Taking stock of the drug industry, from the lab to the medicine chest

July 3, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

KENZO TRIBOUILLARD/AFP via Getty Images GSK buys mRNA-based Covid, flu vaccines from CureVac in restructured partnership CureVac, the German biotech that focuses on mRNA vaccines, will receive an initial payment of €400 million upfront ($430 million) from GSK. By Adam Feuerstein STAT+ | What's next for Cassava Sciences, and Cartesian Therapeutics has a novel excuse for dodgy data Plus: Cartesian Therapeutics' management team comes up with a novel excuse for dodgy data on its mRNA cell therapy for myasthenia gravis. By Adam Feuerstein Study links Ozempic to higher risk of eye condition that can cause vision loss A new study reports for the first time a potential link between Novo Nordisk's GLP-1 drugs Ozempic and Wegovy and an eye condition, NAION. By Elaine Chen Adobe Opinion: Can the National Institutes of Health navigate multiple storms and rebuild its bipartisan support? Several calls for reforming the NIH may be difficult for the agency to fend off without making some concessions. By Nick Manetto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser